FOR IMMEDIATE RELEASE

LEIDOS AWARDED CONTRACT BY DEFENSE HEALTH AGENCY

Health, National Security, and Engineering Solutions Company to Provide Support for the Military Health System Nurse Advice Line

RESTON, Va., Nov. 4, 2013 /PRNewswire/ -- Leidos (NYSE: LDOS), a health, national security, and engineering solutions company, was awarded a prime contract by the Defense Health Agency (DHA) to provide consultative, analytical, decision making, managerial, and implementation support services for a Nurse Advice Line (NAL) that will support the Military Health System (MHS). The single-award firm fixed-price contract has a one-year base period of performance, four one-year options, and a total contract value of approximately $178 million if all options are exercised.

The NAL program is designed to advance the DHA’s goals of improving the availability and quality of care for its beneficiaries while reducing the overall cost of care. NAL beneficiaries will receive around-the-clock access to nurse advice line services where customer calls will be triaged using patented nurse triage algorithms to determine the most appropriate and effective level of care.

Under the contract, Leidos will provide NAL services to more than nine million eligible TRICARE beneficiaries in all 50 states, making it one of the largest and most complex programs of its kind. The scope of work includes call center services, nurse triage services, medical appointing services and administrative support delivered by an expert team of customer service representatives, registered telehealth nurses, and appointment clerks. This team of professionals will provide TRICARE beneficiaries clinical advice and urgent care support based on nationally recognized algorithms, protocols, and guidelines; and enable eligible military enrollees to schedule, cancel, and reschedule appointments through the MHS Composite Health Care System and the Coast Guard’s Epic electronic health record system.

“We are proud to have been selected to work with DHA to provide nurse advice line services to millions of
military beneficiaries across the United States. Improving the availability, quality, and cost effectiveness of healthcare for our military service members and their families are national priorities, and we are honored to support these important goals,” said Steve Comber, group president, Leidos Health.

The company, formerly named Science Applications International Corporation (SAIC), changed its name to Leidos, Inc. on September 27, 2013 [in connection with the spin-off of its former technical, engineering and enterprise information technology business, which has assumed the company's former name]. Leidos has submitted a change-of-name agreement to the U.S. government to recognize the name change, which is currently under review by the responsible Defense Contract Management Agency contracting officer.

About Leidos

Leidos is a science and technology solutions leader working to address some of the world's toughest challenges in national security, health, and engineering. The Company's 23,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes, and defend our Nation's digital and physical infrastructure from 'new world' threats. Leidos is headquartered in Reston, Va. and had approximately $6 billion in revenues for fiscal year 2013, on a pro forma basis, following the spin-off of the company's technical, engineering and enterprise IT business on Sept. 27, 2013. For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in Leidos' Annual Report on Form 10-K for the period ended January 31, 2013, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Contact: Melissa Koskovich (571) 526-6850 Koskovichm@Leidos.com
Jennifer Gephart (703) 676-6389 Gephartja@Leidos.com